Herein, we report a rare case of a patient with ECD diagnosed with genomic profiling harboring both BRAFV600E and KRASG12R mutations simultaneously and who well responded to the combination therapy with encorafenib, a BRAF inhibitor, and binimetinib, a MEK inhibitor. Here, MAP2K7 is linked to familial atrioventricular septal defect.